These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31884656)

  • 41. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Chang AA
    Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
    Puliafito CA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):109. PubMed ID: 23510034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of vascular endothelial growth factor in ocular angiogenesis.
    Shams N; Ianchulev T
    Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration.
    Beck M; Munk MR; Ebneter A; Wolf S; Zinkernagel MS
    Am J Ophthalmol; 2016 Jul; 167():10-7. PubMed ID: 27084000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
    Nishijima K; Ng YS; Zhong L; Bradley J; Schubert W; Jo N; Akita J; Samuelsson SJ; Robinson GS; Adamis AP; Shima DT
    Am J Pathol; 2007 Jul; 171(1):53-67. PubMed ID: 17591953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy.
    Wang JJ; Zhu M; Le YZ
    World J Diabetes; 2015 Jun; 6(5):726-33. PubMed ID: 26069721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
    Campa C; Harding SP
    Curr Drug Targets; 2011 Feb; 12(2):173-81. PubMed ID: 20887245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Characteristics and Clinical Significance of Outer Retinal Tubulation in Wet Age-macular Degeneration Treated by Anti-vascular Endothelial Growth Factor Through Optical Coherence Tomography.].
    Zuo C; Li X; Zhang ZR; Zhang MX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):894-897. PubMed ID: 28598120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.
    Jansen ME; Krambeer CJ; Kermany DS; Waters JN; Tie W; Bahadorani S; Singer J; Comstock JM; Wannamaker KW; Singer MA;
    Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):186-190. PubMed ID: 29554386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
    Nariani A; Williams B; Hariprasad SM
    Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications.
    Cheung N; Wong IY; Wong TY
    Diabetes Care; 2014 Apr; 37(4):900-5. PubMed ID: 24652721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential expression of vascular endothelial growth factor-a isoforms in neovascular age-related macular degeneration.
    Grisanti S; Zhu Q; Tatar O; Lueke J; Lueke M; Tura A; Grisanti S
    Retina; 2015 Apr; 35(4):764-72. PubMed ID: 25494018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clarifying some concepts and clinical significance of refractory or recurrent neovascular age-related macular degeneration].
    Zhao J; Sun X
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):804-7. PubMed ID: 26850580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.